Dyskinesia, Drug-Induced
10
1
1
4
Key Insights
Highlights
Success Rate
57% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
30.0%
3 terminated out of 10 trials
57.1%
-29.4% vs benchmark
20%
2 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (10)
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors
rTMS as an Intervention for Levodopa-induced Dyskinesia
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Safinamide for Levodopa-induced Dyskinesia (PD-LID)
Investigating the Causal Role of preSMA in Levodopa-induced Dyskinesia in Parkinson's Disease
Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)
Movement Disorders Caused by Antipsychotic Drugs in Older Patients
Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia